2009 Letter to Shareholders and Investor Profle
Safe Harbor:
The enclosed documents contain forward-looking statements about Vertex and its drug development candidates, including statements regarding: ongoing and planned drug development activities for telaprevir, VX-770, VX-809, VX-222, VX-765 and VX-509 and our other drug candidates; the data that may be generated by our ongoing and planned clinical trials, and in particular our belief that data from our Phase 3 clinical trials of telaprevir will enable the filing of a New Drug Application in the second half of 2010 and that data from our Phase 3 registration program of VX-770 will enable the filing of a New Drug Application in the second half of 2011; the potential for our drug candidates to improve how serious diseases are treated; our financial strategy and the potential market demand and medical need for telaprevir and our other drug candidates. While we believe that the forward-looking statements contained in these documents are accurate, there are a number of factors that could cause actual events or results to differ materially from those indicated by such forward-looking statements. These risks include the risk that any one or more of our internal or external drug development programs will not proceed as planned for technical, scientific or commercial reasons or due to patient enrollment issues or based on new information from clinical, nonclinical or other sources, and other risks listed under Risk Factors in our reports on Form 10-K and Form 10-Q filed with the Securities and Exchange Commission and available through our website at www.vrtx.com.